Evidence map›Paper›PMID 42819173›Full record

ReviewFrontiers in oncology2026

Mechanisms of resistance to PARP inhibitors in advanced epithelial ovarian cancer: biological determinants and therapeutic implications.

Dalila Incognito, Giuliana Ciappina, Giuseppe Ettore, Carla Ettore, Giosuè Giordano Incognito, Patrizia Carroccio, Emanuela Esposito, Andrea D'Arienzo, Chiara Barraco, Marco Donato and 4 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Dalila Incognito *Medical Oncology Unit, Department of Human Pathology "G. Barresi", School of Specialization in Medical Oncology, University of Messina, Messina, Italy.
Giuliana Ciappina *Department of Medical Sciences, Section of Experimental Medicine, University of Ferrara, Ferrara, Italy.
Giuseppe EttoreObstetrics and Gynecology Unit, Maternal Child Department, ARNAS Garibaldi, Catania, Italy.
Carla EttoreObstetrics and Gynecology Unit, Maternal Child Department, ARNAS Garibaldi, Catania, Italy.
Giosuè Giordano IncognitoObstetrics and Gynecology Unit, Maternal Child Department, ARNAS Garibaldi, Catania, Italy.
Patrizia CarroccioMedical Oncology Unit, Department of Human Pathology "G. Barresi", School of Specialization in Medical Oncology, University of Messina, Messina, Italy.
Emanuela EspositoDepartment of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Messina, Italy.
Andrea D'ArienzoOncology Unit, S. Maria Delle Grazie Hospital, Pozzuoli, Italy.
Chiara BarracoOncology Unit, S. Maria Delle Grazie Hospital, Pozzuoli, Italy.
Marco DonatoDivision of Medical Oncology, AOU "G.Martino" Hospital, University of Messina, Messina, Italy.
Stefano CianciObstetrics and Gynecology Unit, Department of Human Pathology of Adult and Childhood "G. Barresi", University of Messina, Messina, Italy.
Barbara BusàPharmacy Unit, University Hospital "G. Martino", Messina, Italy.
Giordana Di Mauro *Medical Oncology Unit, Department of Human Pathology "G. Barresi", School of Specialization in Medical Oncology, University of Messina, Messina, Italy.
Massimiliano Berretta *Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PARP inhibitors have become an integral component of treatment strategies for advanced epithelial ovarian cancer, particularly in

Indexed as

DNA repairdrug resistancehomologous recombinationovarian carcinomapoly(ADP-ribose) polymerase inhibitorsrecombinational DNA repair

Identifiers

PMID42819173
PMCPMC13625177

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.